194726-40-4

Usage

Uses

Used in Pharmaceutical Industry:
(R)-1-BOC-3-HYDROXYMETHYLPIPERIDINE ETHYL ESTER is used as a building block for the synthesis of various pharmaceuticals and organic compounds. Its unique structure and functional groups contribute to its versatility in drug discovery and development, allowing for the creation of new drug candidates and active pharmaceutical ingredients.
Used in Drug Discovery:
(R)-1-BOC-3-HYDROXYMETHYLPIPERIDINE ETHYL ESTER is utilized as a key component in the development of new drug candidates. Its chemical properties and protective BOC group enable the synthesis of complex molecules with potential therapeutic applications.
Used in Active Pharmaceutical Ingredients (API) Production:
(R)-1-BOC-3-HYDROXYMETHYLPIPERIDINE ETHYL ESTER is employed in the production of active pharmaceutical ingredients. Its role in the synthesis process ensures the creation of effective and stable APIs for various medicinal applications.

InChI:InChI=1/C13H23NO4/c1-5-17-11(15)10-7-6-8-14(9-10)12(16)18-13(2,3)4/h10H,5-9H2,1-4H3/t10-/m1/s1

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 163343-71-3 (R)-3-piperidinecarboxylic acid ethyl ester (+)-tartrate 
• 25137-01-3 (R)-ethyl nipecotate 
• 163343-71-3 (R)-piperidine-3-carboxylic acid ethyl ester*l-tartaric acid 
• 917112-58-4 5,6-dihydro-4H-pyridine-1,3-dicarboxylic acid 1-tert-butyl ester 3-ethyl ester 
• 614-18-6 3-pyridinecarboxylic acid ethyl ester 
• 3335-05-5 ethyl 1,4,5,6-tetrahydropyridine-3-carboxylate 
• 75-03-6 ethyl iodide 
• 163438-09-3 (R)-1-Boc-nipecotic acid 
• 498-95-3 (R)-nipecotic acid 

Downstream Products

• 194726-46-0 (3R)-3-formylpiperidine-1-carboxylic acid tert-butyl ester 
• 254905-64-1 (3S)-3-(dimethylaminomethyl)piperidine-1-carboxylic acid tert-butyl ester 
• 384830-08-4 tert-butyl (3R)-3-(iodomethyl) piperidine-1-carboxylate 
• 384830-09-5 (S)-3-((2S,3R)-2-Benzyloxycarbonyl-4-oxo-azetidin-3-ylmethyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 384830-10-8 (2S,3R)-3-((S)-1-{Benzyloxycarbonylamino-[(E)-benzyloxycarbonylimino]-methyl}-piperidin-3-ylmethyl)-4-oxo-azetidine-2-carboxylic acid benzyl ester 
• 384830-11-9 (2S,3R)-3-((S)-1-{Benzyloxycarbonylamino-[(E)-benzyloxycarbonylimino]-methyl}-piperidin-3-ylmethyl)-4-oxo-1-[4-(6-phenyl-hexanoyl)-piperazine-1-carbonyl]-azetidine-2-carboxylic acid benzyl ester 
• 1436861-98-1 trans-3-[N'-(6-benzyloxy-7-oxo-1,6-diaza-bicyclo[3.2.1]octane-2-carbonyl)-hydrazinocarbonyl]-(R)-piperidin-1-carboxylic acid tert-butyl ester 
• 1436861-97-0 Zidebactam 
• 1374351-11-7 (R)-5-(5-(1-(2-fluoro-6-methoxybenzyl)piperidin-3-yl)-1H-1,2,4-triazol-3-yl)-3-(pyridin-4-yl)-1H-indazole 
• 1374353-13-5 (R)-tert-butyl 3-(3-(3-(pyridin-4-yl)-1-trityl-1H-indazol-5-yl)-1H-1,2,4-triazol-5-yl)piperidine-1-carboxylate 
• 1374353-11-3 (R)-tert-butyl 3-(3-(3-bromo-1-trityl-1H-indazol-5-yl)-1H-1,2,4-triazol-5-yl)piperidine-1-carboxylate 
• 1374353-12-4 C₅₇H₅₁BrN₆O₂ 
• 1002359-83-2 (R)-3-(hydrazinecarbonyl)piperidine-1-carboxylic acid tert-butyl ester 
• 163438-09-3 (R)-1-Boc-nipecotic acid 

Relevant academic research and scientific papers

9-SUBSTITUTED AMINO TRIAZOLO QUINAZOLINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE

In its many embodiments, the present invention provides certain 9-substituted amino triazolo quinazoline compounds of the structural Formula (I): (I), and pharmaceutically acceptable salts thereof, wherein, ring A, R1 and R2 are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutically active agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.

Synthetic method for (R)-N-tert-butoxycarbonyl-3-hydroxymethylpiperidine

The invention discloses a synthetic method for (R)-N-tert-butoxycarbonyl-3-hydroxymethylpiperidine. The method comprises the following four steps: synthesizing ethyl 3-piperidinecarboxylate (compoundII), synthesizing ethyl (R)-nipecotate-L-tartarate (compound III), synthesizing ethyl (R)-N-Boc-3-piperidinecarboxylate (compound IV) and synthesizing the (R)-N-tert-butoxycarbonyl-3-hydroxymethylpiperidine (compound V); and the method comprises the following special steps: synthesizing the compound II by using 3-piperidinecarboxylic acid (compound I) as a raw material through chloroacylation andethanol esterification; performing a salt formation reaction to form the compound III; adding a Boc anhydride and performing a reaction to obtain the compound IV; and finally performing sodium borohydride reduction to obtain the compound V. The method provided by the invention has the advantages of mild reaction conditions, environmental friendliness, simple operation steps, better reproducibilityand high practicability, and is suitable for industrial mass production of the (R)-N-tert-butoxycarbonyl-3-hydroxymethylpiperidine.

Process for preparation of (2S, 5R)-7-oxo-6-sulphooxy-2[((3R)-piperidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo [3.2.1]-octane

A process for preparation of (2S,5R)-7-oxo-6-sulphooxy-2-[((3R)-piperidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo[3.2.1]octane of Formula (I) is disclosed which is comprising reacting a compound of Formula (II) with a compound of Formula (III) to obtain a compound of Formula (IV). Crystalline compounds of Formula (I) are claimed.

A PROCESS FOR PREPARATION OF (2S, 5R)-7-OXO-6-SULPHOOXY-2-[((3R)-PIPERIDINE-3-CARBONYL)-HYDRAZINO CARBONYL]-1,6-DIAZA-BICYCLO [3.2.1]- OCTANE

A process for preparation of (2S, 5R)-7-oxo-6-sulphooxy-2- [((3R)-piperidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza- bicyclo[3.2.1]octane of Formula (I) is disclosed which is comprising reacting a compound of Formula (II) with a compound of Formula (III) to obtain a compound of Formula (IV). Crystalline compounds of Formula (I) are claimed.

Novel non-peptide nociceptin/orphanin FQ receptor agonist, 1-[1-(1-Methylcyclooctyl)-4-piperidinyl]-2-[(3R)-3-piperidinyl] -1H-benzimidazole: Design, synthesis, and structure-activity relationship of oral receptor occupancy in the brain for orally potent

An endogenous heptadecapeptide, nociceptin/orphanin FQ (N/OFQ), and a G-protein-coupled receptor, N/OFQ peptide (NOP) receptor [or opioid-receptor-like-1 (ORL1) receptor], have been described in terms of its structure, distribution, and pharmacology. Thus

4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: Design, synthesis and structure-activity relationships

Single enantiomer [(aryloxy)(pyridinyl)methyl]piperidine and pyrrolidine derivatives 5-9 are inhibitors of monoamine reuptake. Structure-activity relationships established that monoamine reuptake inhibition are functions of amine, pyridine isomer, aryloxy ring substitution and stereochemistry. Consequently, selective NRIs, selective SRIs, dual SNRIs and triple SNDRIs were all identified. Dual SNRIs 5l-a and 9c were evaluated in additional pharmacology and pharmacokinetic studies as representative examples from this series.

Asymmetric hydrogenation of pyridines: Enantioselective synthesis of nipecotic acid derivatives

An asymmetric hydrogenation process of 3-substituted pyridine derivatives has been developed with the use of a Rh-TangPhos complex as the catalyst. The whole process consists of an efficient partial hydrogenation of nicotinate and a subsequent highly enan

Compounds with growth hormone releasing properties

Disclosed are compounds of formula I formula I wherein R1, R2, R5, R6, R7, R8, G, J, L, M, a, b, c, d, e, and f are as defined in the specification, and compositions containing them. These

Synthesis of potent and highly selective inhibitors of human tryptase

The serine protease tryptase has been implicated in allergic and inflammatory diseases and associated with asthma. The synthesis and SAR of a series of N1-activated-4-carboxy azetidinones are described, resulting in identification of BMS-363131 (2) as a potent inhibitor of human tryptase (IC503000-fold) for tryptase versus related serine proteases including trypsin.

Beta lactam compounds and their use as inhibitors of tryptase

Compounds of the formulas: are disclosed. These compounds inhibit tryptase as well as other enzyme systems or are selective tryptase inhibitors and are useful as antiinflammatory agents particularly in the treatment of chronic asthma.